{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T22:49:55Z","timestamp":1773787795360,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,11,5]],"date-time":"2016-11-05T00:00:00Z","timestamp":1478304000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["442302"],"award-info":[{"award-number":["442302"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Causes Control"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s10552-016-0824-4","type":"journal-article","created":{"date-parts":[[2016,11,5]],"date-time":"2016-11-05T06:42:27Z","timestamp":1478328147000},"page":"1457-1464","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Nonsteroidal anti-inflammatory drugs, statins, and pancreatic cancer risk: a population-based case\u2013control study"],"prefix":"10.1007","volume":"27","author":[{"given":"Pik Fang","family":"Kho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Fawcett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Fritschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harvey","family":"Risch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penelope M.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Whiteman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7162-0854","authenticated-orcid":false,"given":"Rachel E.","family":"Neale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,5]]},"reference":[{"key":"824_CR1","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359\u2013E386","journal-title":"Int J Cancer"},{"key":"824_CR2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/ajco.12062","volume":"9","author":"Australian Institute of Health and Welfare","year":"2013","unstructured":"Australian Institute of Health and Welfare (2013) Cancer survival and prevalence in Australia: period estimates from 1982 to 2010. Asia Pac J Clin Oncol 9:29\u201339","journal-title":"Asia Pac J Clin Oncol"},{"key":"824_CR3","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.ejca.2013.12.014","volume":"50","author":"A Schulte","year":"2014","unstructured":"Schulte A, Pandeya N, Tran B, Fawcett J, Fritschi L, Risch HA, Webb PM, Whiteman DC, Neale RE, Queensland Pancreatic Cancer Study G (2014) Cigarette smoking and pancreatic cancer risk: more to the story than just pack-years. Eur J Cancer 50:997\u20131003","journal-title":"Eur J Cancer"},{"key":"824_CR4","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.7314\/APJCP.2014.15.11.4643","volume":"15","author":"BL Zhang","year":"2014","unstructured":"Zhang BL, He N, Huang YB, Song FJ, Chen KX (2014) ABO blood groups and risk of cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev 15:4643\u20134650","journal-title":"Asian Pac J Cancer Prev"},{"key":"824_CR5","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/PPO.0b013e3182756803","volume":"18","author":"TP Yeo","year":"2012","unstructured":"Yeo TP, Lowenfels AB (2012) Demographics and epidemiology of pancreatic cancer. Cancer J 18:477\u2013484","journal-title":"Cancer J"},{"key":"824_CR6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/mc.20778","volume":"51","author":"PM Bracci","year":"2012","unstructured":"Bracci PM (2012) Obesity and pancreatic cancer: overview of epidemiologic evidence and biologic mechanisms. Mol Carcinog 51:53\u201363","journal-title":"Mol Carcinog"},{"key":"824_CR7","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1158\/1055-9965.EPI-10-1196","volume":"20","author":"RC Eldridge","year":"2011","unstructured":"Eldridge RC, Gapstur SM, Newton CC, Goodman M, Patel AV, Jacobs EJ (2011) Jewish ethnicity and pancreatic cancer mortality in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev 20:691\u2013698","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"824_CR8","doi-asserted-by":"crossref","first-page":"215985","DOI":"10.1155\/2011\/215985","volume":"2011","author":"R Lochan","year":"2011","unstructured":"Lochan R, Daly AK, Reeves HL, Charnley RM (2011) Family history of cancer and tobacco exposure in index cases of pancreatic ductal adenocarcinoma. J Oncol 2011:215985","journal-title":"J Oncol"},{"key":"824_CR9","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.puhe.2013.04.008","volume":"127","author":"HL Lin","year":"2013","unstructured":"Lin HL, An QZ, Wang QZ, Liu CX (2013) Folate intake and pancreatic cancer risk: an overall and dose-response meta-analysis. Public Health 127:607\u2013613","journal-title":"Public Health"},{"key":"824_CR10","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/aje\/kwt052","volume":"178","author":"SH Olson","year":"2013","unstructured":"Olson SH, Hsu M, Satagopan JM, Maisonneuve P, Silverman DT, Lucenteforte E, Anderson KE, Borgida A, Bracci PM, Bueno-de-Mesquita HB, Cotterchio M, Dai Q, Duell EJ, Fontham EH, Gallinger S, Holly EA, Ji BT, Kurtz RC, La Vecchia C, Lowenfels AB, Luckett B, Ludwig E, Petersen GM, Polesel J, Seminara D, Strayer L, Talamini R, Pancreatic Cancer Case-Control C (2013) Allergies and risk of pancreatic cancer: a pooled analysis from the Pancreatic Cancer Case-Control Consortium. Am J Epidemiol 178:691\u2013700","journal-title":"Am J Epidemiol"},{"key":"824_CR11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/aje\/kws027","volume":"176","author":"A Koushik","year":"2012","unstructured":"Koushik A, Spiegelman D, Albanes D, Anderson KE, Bernstein L, van den Brandt PA, Bergkvist L, English DR, Freudenheim JL, Fuchs CS, Genkinger JM, Giles GG, Goldbohm RA, Horn-Ross PL, Mannisto S, McCullough ML, Millen AE, Miller AB, Robien K, Rohan TE, Schatzkin A, Shikany JM, Stolzenberg-Solomon RZ, Willett WC, Wolk A, Ziegler RG, Smith-Warner SA (2012) Intake of fruits and vegetables and risk of pancreatic cancer in a pooled analysis of 14 cohort studies. Am J Epidemiol 176:373\u2013386","journal-title":"Am J Epidemiol"},{"key":"824_CR12","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1002\/ijc.24997","volume":"126","author":"MA O\u2019Rorke","year":"2010","unstructured":"O\u2019Rorke MA, Cantwell MM, Cardwell CR, Mulholland HG, Murray LJ (2010) Can physical activity modulate pancreatic cancer risk? A systematic review and meta-analysis. Int J Cancer 126:2957\u20132968","journal-title":"Int J Cancer"},{"key":"824_CR13","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1093\/jnci\/94.15.1168","volume":"94","author":"KE Anderson","year":"2002","unstructured":"Anderson KE, Johnson TW, Lazovich D, Folsom AR (2002) Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer. J Natl Cancer Inst 94:1168\u20131171","journal-title":"J Natl Cancer Inst"},{"key":"824_CR14","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1158\/1055-9965.EPI-13-1284","volume":"23","author":"SA Streicher","year":"2014","unstructured":"Streicher SA, Yu H, Lu L, Kidd MS, Risch HA (2014) Case\u2013control study of aspirin use and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 23:1254\u20131263","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"824_CR15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/MPA.0b013e3182a8d41f","volume":"43","author":"XJ Cui","year":"2014","unstructured":"Cui XJ, He Q, Zhang JM, Fan HJ, Wen ZF, Qin YR (2014) High-dose aspirin consumption contributes to decreased risk for pancreatic cancer in a systematic review and meta-analysis. Pancreas 43:135\u2013140","journal-title":"Pancreas"},{"key":"824_CR16","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1158\/1940-6207.CAPR-11-0146","volume":"4","author":"XL Tan","year":"2011","unstructured":"Tan XL, Reid Lombardo KM, Bamlet WR, Oberg AL, Robinson DP, Anderson KE, Petersen GM (2011) Aspirin, nonsteroidal anti-inflammatory drugs, acetaminophen, and pancreatic cancer risk: a clinic-based case\u2013control study. Cancer Prev Res 4:1835\u20131841","journal-title":"Cancer Prev Res"},{"key":"824_CR17","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/sj.bjc.6605636","volume":"102","author":"MC Bradley","year":"2010","unstructured":"Bradley MC, Hughes CM, Cantwell MM, Napolitano G, Murray LJ (2010) Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case\u2013control study. Br J Cancer 102:1415\u20131421","journal-title":"Br J Cancer"},{"key":"824_CR18","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/CEJ.0b013e32833b48a4","volume":"19","author":"M Bonifazi","year":"2010","unstructured":"Bonifazi M, Gallus S, Bosetti C, Polesel J, Serraino D, Talamini R, Negri E, La Vecchia C (2010) Aspirin use and pancreatic cancer risk. Eur J Cancer Prev 19:352\u2013354","journal-title":"Eur J Cancer Prev"},{"key":"824_CR19","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/j.1365-2036.2007.03495.x","volume":"26","author":"G Capurso","year":"2007","unstructured":"Capurso G, Schunemann HJ, Terrenato I, Moretti A, Koch M, Muti P, Capurso L, Delle Fave G (2007) Meta-analysis: the use of non-steroidal anti-inflammatory drugs and pancreatic cancer risk for different exposure categories. Aliment Pharmacol Ther 26:1089\u20131099","journal-title":"Aliment Pharmacol Ther"},{"key":"824_CR20","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1158\/1055-9965.EPI-06-0574","volume":"15","author":"SC Larsson","year":"2006","unstructured":"Larsson SC, Giovannucci E, Bergkvist L, Wolk A (2006) Aspirin and nonsteroidal anti-inflammatory drug use and risk of pancreatic cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15:2561\u20132564","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"824_CR21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(10)62110-1","volume":"377","author":"PM Rothwell","year":"2011","unstructured":"Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377:31\u201341","journal-title":"Lancet"},{"key":"824_CR22","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S0140-6736(11)61720-0","volume":"379","author":"PM Rothwell","year":"2012","unstructured":"Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, Lee R, Belch JF, Wilson M, Mehta Z, Meade TW (2012) Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379:1602\u20131612","journal-title":"Lancet"},{"key":"824_CR23","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1007\/s10552-010-9628-0","volume":"21","author":"MC Bradley","year":"2010","unstructured":"Bradley MC, Hughes CM, Cantwell MM, Murray LJ (2010) Statins and pancreatic cancer risk: a nested case\u2013control study. Cancer Causes Control 21:2093\u20132100","journal-title":"Cancer Causes Control"},{"key":"824_CR24","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2174\/156800905774932824","volume":"5","author":"J Dulak","year":"2005","unstructured":"Dulak J, Jozkowicz A (2005) Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Curr Cancer Drug Targets 5:579\u2013594","journal-title":"Curr Cancer Drug Targets"},{"key":"824_CR25","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s10552-012-9979-9","volume":"23","author":"X Cui","year":"2012","unstructured":"Cui X, Xie Y, Chen M, Li J, Liao X, Shen J, Shi M, Li W, Zheng H, Jiang B (2012) Statin use and risk of pancreatic cancer: a meta-analysis. Cancer Causes Control 23:1099\u20131111","journal-title":"Cancer Causes Control"},{"key":"824_CR26","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1111\/j.1572-0241.2008.02051.x","volume":"103","author":"S Bonovas","year":"2008","unstructured":"Bonovas S, Filioussi K, Sitaras NM (2008) Statins are not associated with a reduced risk of pancreatic cancer at the population level, when taken at low doses for managing hypercholesterolemia: evidence from a meta-analysis of 12 studies. Am J Gastroenterol 103:2646\u20132651","journal-title":"Am J Gastroenterol"},{"key":"824_CR27","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/cncr.29256","volume":"121","author":"EJ Walker","year":"2015","unstructured":"Walker EJ, Ko AH, Holly EA, Bracci PM (2015) Statin use and risk of pancreatic cancer: results from a large, clinic-based case\u2013control study. Cancer 121:1287\u20131294","journal-title":"Cancer"},{"key":"824_CR28","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1007\/s10620-013-2778-7","volume":"58","author":"FJ Carey","year":"2013","unstructured":"Carey FJ, Little MW, Pugh TF, Ndokera R, Ing H, Clark A, Dennison A, Metcalfe MS, Robinson RJ, Hart AR (2013) The differential effects of statins on the risk of developing pancreatic cancer: a case\u2013control study in two centres in the United Kingdom. Dig Dis Sci 58:3308\u20133312","journal-title":"Dig Dis Sci"},{"key":"824_CR29","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1445-2197.2012.06312.x","volume":"83","author":"N Wylie","year":"2013","unstructured":"Wylie N, Adib R, Barbour AP, Fawcett J, Hill A, Lynch S, Martin I, O\u2019Rourke TR, Puhalla H, Rutherford L, Slater K, Whiteman DC, Neale RE, Queensland Pancreatic Cancer Study G (2013) Surgical management in patients with pancreatic cancer: a Queensland perspective. ANZ J Surg 83:859\u2013864","journal-title":"ANZ J Surg"},{"key":"824_CR30","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1186\/1471-2407-12-582","volume":"12","author":"YH Yang","year":"2012","unstructured":"Yang YH, Yang YH, Cheng CL, Ho PS, Ko YC (2012) The role of chemoprevention by selective cyclooxygenase-2 inhibitors in colorectal cancer patients\u2014a population-based study. BMC Cancer 12:582","journal-title":"BMC Cancer"},{"key":"824_CR31","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa061652","volume":"355","author":"N Arber","year":"2006","unstructured":"Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B, Pre SAPTI (2006) Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355:885\u2013895","journal-title":"N Engl J Med"},{"key":"824_CR32","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1053\/j.gastro.2006.08.079","volume":"131","author":"JA Baron","year":"2006","unstructured":"Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A, Bolognese JA, Oxenius B, Horgan K, Loftus S, Morton DG, Investigators APT (2006) A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 131:1674\u20131682","journal-title":"Gastroenterology"},{"key":"824_CR33","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1056\/NEJMoa061355","volume":"355","author":"MM Bertagnolli","year":"2006","unstructured":"Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET, Investigators APCS (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355:873\u2013884","journal-title":"N Engl J Med"},{"key":"824_CR34","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.breast.2010.07.004","volume":"20","author":"V Ashok","year":"2011","unstructured":"Ashok V, Dash C, Rohan TE, Sprafka JM, Terry PD (2011) Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk. Breast 20:66\u201370","journal-title":"Breast"},{"key":"824_CR35","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/pros.22815","volume":"74","author":"J Bieniek","year":"2014","unstructured":"Bieniek J, Childress C, Swatski MD, Yang W (2014) COX-2 inhibitors arrest prostate cancer cell cycle progression by down-regulation of kinetochore\/centromere proteins. Prostate 74:999\u20131011","journal-title":"Prostate"},{"key":"824_CR36","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3109\/10520295.2012.724713","volume":"88","author":"VR Katkoori","year":"2013","unstructured":"Katkoori VR, Manne K, Vital-Reyes VS, Rodriguez-Burford C, Shanmugam C, Sthanam M, Manne U, Chatla C, Abdulkadir SA, Grizzle WE (2013) Selective COX-2 inhibitor (celecoxib) decreases cellular growth in prostate cancer cell lines independent of p53. Biotech Histochem 88:38\u201346","journal-title":"Biotech Histochem"},{"key":"824_CR37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.toxlet.2013.12.014","volume":"225","author":"S Zhang","year":"2014","unstructured":"Zhang S, Da L, Yang X, Feng D, Yin R, Li M, Zhang Z, Jiang F, Xu L (2014) Celecoxib potentially inhibits metastasis of lung cancer promoted by surgery in mice, via suppression of the PGE2-modulated beta-catenin pathway. Toxicol Lett 225:201\u2013207","journal-title":"Toxicol Lett"},{"key":"824_CR38","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1620\/tjem.215.149","volume":"215","author":"XF Xu","year":"2008","unstructured":"Xu XF, Xie CG, Wang XP, Liu J, Yu YC, Hu HL, Guo CY (2008) Selective inhibition of cyclooxygenase-2 suppresses the growth of pancreatic cancer cells in vitro and in vivo. Tohoku J Exp Med 215:149\u2013157","journal-title":"Tohoku J Exp Med"},{"key":"824_CR39","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/jcb.22523","volume":"110","author":"S Ali","year":"2010","unstructured":"Ali S, Banerjee S, Schaffert JM, El-Rayes BF, Philip PA, Sarkar FH (2010) Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer. J Cell Biochem 110:171\u2013181","journal-title":"J Cell Biochem"},{"key":"824_CR40","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1158\/0008-5472.CAN-03-1945","volume":"64","author":"D Wei","year":"2004","unstructured":"Wei D, Wang L, He Y, Xiong HQ, Abbruzzese JL, Xie K (2004) Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res 64:2030\u20132038","journal-title":"Cancer Res"},{"key":"824_CR41","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000049449","volume":"2","author":"FA Wenger","year":"2002","unstructured":"Wenger FA, Kilian M, Achucarro P, Heinicken D, Schimke I, Guski H, Jacobi CA, Muller JM (2002) Effects of Celebrex and Zyflo on BOP-induced pancreatic cancer in Syrian hamsters. Pancreatology 2:54\u201360","journal-title":"Pancreatology"},{"key":"824_CR42","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/1097-0142(20010115)91:2<333::AID-CNCR1006>3.0.CO;2-N","volume":"91","author":"A Kokawa","year":"2001","unstructured":"Kokawa A, Kondo H, Gotoda T, Ono H, Saito D, Nakadaira S, Kosuge T, Yoshida S (2001) Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer 91:333\u2013338","journal-title":"Cancer"},{"key":"824_CR43","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1023\/A:1027319903359","volume":"20","author":"J Okami","year":"2003","unstructured":"Okami J, Nakamori S, Hiraoka N, Tsujie M, Hayashi N, Yamamoto H, Fujiwara Y, Nagano H, Dono K, Umeshita K, Sakon M, Monden M (2003) Suppression of pancreatic cancer cell invasion by a cyclooxygenase-2-specific inhibitor. Clin Exp Metastasis 20:577\u2013584","journal-title":"Clin Exp Metastasis"},{"key":"824_CR44","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1476-4598-4-27","volume":"4","author":"S Yoshida","year":"2005","unstructured":"Yoshida S, Ujiki M, Ding XZ, Pelham C, Talamonti MS, Bell RH Jr, Denham W, Adrian TE (2005) Pancreatic stellate cells (PSCs) express cyclooxygenase-2 (COX-2) and pancreatic cancer stimulates COX-2 in PSCs. Mol Cancer 4:27","journal-title":"Mol Cancer"},{"key":"824_CR45","first-page":"1737","volume":"8","author":"S Li","year":"2015","unstructured":"Li S, Gu Z, Xiao Z, Zhou T, Li J, Sun K (2015) Anti-tumor effect and mechanism of cyclooxygenase-2 inhibitor through matrix metalloproteinase 14 pathway in PANC-1 cells. Int J Clin Exp Pathol 8:1737\u20131742","journal-title":"Int J Clin Exp Pathol"},{"key":"824_CR46","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/ajg.2008.33","volume":"104","author":"F Bergmann","year":"2009","unstructured":"Bergmann F, Breinig M, Hopfner M, Rieker RJ, Fischer L, Kohler C, Esposito I, Kleeff J, Herpel E, Ehemann V, Friess H, Schirmacher P, Kern MA (2009) Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors? Am J Gastroenterol 104:171\u2013181","journal-title":"Am J Gastroenterol"},{"key":"824_CR47","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1097\/00029330-200710020-00004","volume":"120","author":"HY Wang","year":"2007","unstructured":"Wang HY, Yang YM, Zhuang Y, Chen HN, Wan YL, Huang YT (2007) The effect of celecoxib on tissue factor expression in pancreatic cancer cells. Chin Med J (Engl) 120:1753\u20131756","journal-title":"Chin Med J (Engl)"},{"key":"824_CR48","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.cct.2013.09.014","volume":"36","author":"Group AI","year":"2013","unstructured":"Group AI (2013) Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. Contemp Clin Trials 36:555\u2013564","journal-title":"Contemp Clin Trials"},{"key":"824_CR49","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/MPA.0b013e31821fd5cd","volume":"40","author":"HF Chiu","year":"2011","unstructured":"Chiu HF, Chang CC, Ho SC, Wu TN, Yang CY (2011) Statin use and the risk of pancreatic cancer: a population-based case\u2013control study. Pancreas 40:669\u2013672","journal-title":"Pancreas"},{"key":"824_CR50","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s10552-016-0717-6","volume":"27","author":"MS Simon","year":"2016","unstructured":"Simon MS, Desai P, Wallace R, Wu C, Howard BV, Martin LW, Schlecht N, Liu S, Jay A, LeBlanc ES, Rohan T, Manson J (2016) Prospective analysis of association between statins and pancreatic cancer risk in the Women\u2019s Health Initiative. Cancer Causes Control 27:415\u2013423","journal-title":"Cancer Causes Control"},{"key":"824_CR51","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s11883-009-0016-8","volume":"11","author":"AA Alsheikh-Ali","year":"2009","unstructured":"Alsheikh-Ali AA, Karas RH (2009) The relationship of statins to rhabdomyolysis, malignancy, and hepatic toxicity: evidence from clinical trials. Curr Atheroscler Rep 11:100\u2013104","journal-title":"Curr Atheroscler Rep"}],"container-title":["Cancer Causes &amp; Control"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-016-0824-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10552-016-0824-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-016-0824-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T11:10:56Z","timestamp":1718881856000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10552-016-0824-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,5]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["824"],"URL":"https:\/\/doi.org\/10.1007\/s10552-016-0824-4","relation":{},"ISSN":["0957-5243","1573-7225"],"issn-type":[{"value":"0957-5243","type":"print"},{"value":"1573-7225","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,5]]}}}